[#DIV28SUPER] National Institute on Drug Abuse Request for Applications (RFAs) for HIV/AIDS research

Table of Contents:

 

I.      NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding

(NOT-OD-15-137)

National Institutes of Health

Office of AIDS Research

2.    Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01)
(RFA-DA-16-012)
National Institute on Drug Abuse
Application Receipt Date(s): March 02, 2016

3.    Systems Biology Approaches in HIV/AIDS and Substance Use (R01)
(RFA-DA-16-013)
National Institute on Drug Abuse
Application Receipt Date(s): April 04, 2016

4.    Effects of Drugs of Abuse on Latent HIV Reservoirs in the CNS (R01)
(RFA-DA-16-014)
National Institute on Drug Abuse
Application Receipt Date(s): March 3, 2016 by 5:00 PM local time of applicant organization

5.    Seek, Test, Treat and Retain For Youth and Young Adults Living with or at High Risk for Acquiring HIV (R01)

(RFA-DA-16-010)

National Institute on Drug Abuse

Application Receipt Date(s): March 2, 2016, by 5:00 PM local time of applicant organization.

 

1.    NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding

(NOT-OD-15-137)

National Institutes of Health

Office of AIDS Research

The purpose of this Notice is to inform the scientific community of the overarching HIV/AIDS research priorities and the guidelines NIH will use for determining AIDS funding beginning in fiscal year 2016 for the next three to five years. (Please read entire notice for details)

 

2.    Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01)
(RFA-DA-16-012)
National Institute on Drug Abuse
Application Receipt Date(s): March 02, 2016

The goal of this Funding Opportunity Announcement (FOA) is to stimulate innovative hypothesis-driven research to enhance our understanding of the role of epigenomic or non-coding RNA regulatory mechanisms in HIV/AIDS infection or disease trajectory in combination with substance use or abuse.  We are particularly interested in understanding regulatory mechanisms that influence selection and regulation of HIV sites of integration in the host genome.  A deeper understanding of these mechanisms could lead to novel approaches for monitoring latent HIV in cellular reservoirs, especially in the central nervous system.  Ultimately, research in this area could enable the identification of molecular targets that could be manipulated either to eliminate or permanently repress HIV in cellular reservoirs. (Please read entire Funding Opportunity Announcement for details) 

 

3.    Systems Biology Approaches in HIV/AIDS and Substance Use (R01)
(RFA-DA-16-013)
National Institute on Drug Abuse
Application Receipt Date(s): April 04, 2016

The purpose of this Funding Opportunity Announcement (FOA) is to support systems biology research projects that address critical questions in HIV/AIDS research in the context of drugs of abuse.  Substance use and abuse present unique challenges for HIV prevention, treatment, disease progression, medical consequences, potential cure, and responses to vaccines or therapeutics.  Understanding the complex biological intersection of HIV/AIDS and substance use and abuse is the central theme of this FOA.  (Please read entire Funding Opportunity Announcement for details)

 

 

4.    Effects of Drugs of Abuse on Latent HIV Reservoirs in the CNS (R01)
(RFA-DA-16-014)
National Institute on Drug Abuse
Application Receipt Date(s): March 3, 2016 by 5:00 PM local time of applicant

The purpose of this FOA is to promote research to investigate the underlying molecular mechanisms by which HIV latency is initiated, established, and maintained in the CNS and to determine how drugs of abuse modulate HIV latency and the size and persistence of CNS HIV reservoirs. The ultimate goal is to obtain information for developing new or improved therapies for HIV treatment in drug-abusing populations. (Please read entire Funding Opportunity Announcement for details)

 

 

5.    Seek, Test, Treat and Retain For Youth and Young Adults Living with or at High Risk for Acquiring HIV (R01)

(RFA-DA-16-010)

National Institute on Drug Abuse

Application Receipt Date(s): March 2, 2016, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to examine seek, test, treat and retain approaches among youth and young adults (ages 13-25) who are at high risk for HIV acquisition or have already acquired HIV. Applications should incorporate substance use into study aims; objectives should address substance use prevention, screening, and/or treatment in ways that facilitate use of HIV prevention and treatment services. Youth are the target of this RFA because they demonstrate lower levels of screening and engagement across the HIV continuum of care and HIV+ youth are less likely to achieve viral suppression than those at older ages. These disparities are evident in US and foreign populations. The developmental, structural, and systemic factors related to serving youth need to be clearly incorporated into study aims, rather than simple incremental refocusing of existing interventions to younger people. Both domestic and international projects will be supported. (Please read entire Funding Opportunity Announcement for details)

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov     301-435-1309

 

 

 

Re: [#DIV28SUPER] MA in clinical psychopharmacology at University of Hawai'i Hilo an APA designee

Great news!

Joseph D ( Dan) Eubanks, Ph. D., ABPP/CN
Kailua-Kona, Hawaii

_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

[#DIV28SUPER] MA in clinical psychopharmacology at University of Hawai'i Hilo an APA designee

The master of science in clinical psychopharmacology (MSCP) program offered through the Daniel K. Inouye College of Pharmacy at the University of Hawaiʻi at Hilo has been granted American Psychological Association (APA) designation.

http://www.hawaii.edu/news/2015/12/18/psychopharmacology-program-gains-apa-approval/

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

[#DIV28SUPER] UVM NIH POSTDOCTORAL RESEARCH FELLOWSHIP POSITION

NIH Postdoctoral Research Fellowship Opportunity

The University of Vermont's Center on Behavior and Health announces an
NIH postdoctoral research fellowship opportunity in our
internationally recognized center of excellence for the study of
substance abuse. The fellow will participate in the conduct of an
ongoing NIDA-funded trial to develop a novel buprenorphine treatment
for opioid-dependent adults, as well as develop new research
opportunities in related areas. The mentoring team has an exceptional
track record of helping fellows further their careers as investigators.

Appointment: 2-3 yrs.

Eligibility: Applicants must have completed their training in
psychology, behavior analysis, or a related discipline and be U.S.
citizens or permanent residents. Trainees are selected on the basis
of scholastic record and commitment to a career in substance abuse
research. Individuals must be highly motivated, possess initiative and
a desire to learn and expand their interests and expertise.

Benefits: Stipend, medical insurance coverage, and travel funds
supported by NIH Institutional Training Awards.

For more information: Contact Ms. Diana Cain (Diana.Cain@uvm.edu).

To apply: Send cover letter (downloaded from VCBH website), curriculum
vitae, statement of research interests, and 3 letters of reference to:
Dr. Stacey Sigmon c/o Ms. Diana Cain (Diana.Cain@uvm.edu).

About us: The Vermont Center on Behavior and Health (VCBH) was
established in 2013, sponsored in part by a Centers of Biomedical
Research Excellence (COBRE) Award from the National Institute on
General Medical Sciences and a Centers of Tobacco Regulatory Science
(TCORS) Award from the National Institute on Drug Abuse.

The VCBH resides within the College of Medicine at the University of
Vermont, with the director and administrative offices being located
within the Department of Psychiatry, and participating investigators,
collaborators, and advisors across 15 academic departments in the
College of Medicine and 7 colleges within the University of Vermont
and5 other universities. The VCBH is further strengthened by
interdisciplinary collaborations with key community healthcare leaders
and distinguished scientific advisory panels.
The focus of the VCBH is on investigating relationships between
personal behaviors and risk for chronic disease and premature death,
with a specific focus on understanding mechanisms underpinning risk,
and developing effective interventions and policies to promote healthy
behavior.

See our website for further details:
https://www.uvm.edu/medicine/behaviorandhealth/

About Burlington, Vermont: Burlington, Vermont is located in the
beautiful Lake Champlain region, surrounded by the Green and
Adirondack Mountains. It is a great place for families, boasting
excellent schools and year-round recreational opportunities. It is
home to the University of Vermont and many other colleges that provide
an academically stimulating and culturally rich environment. Montreal
and Boston are within easy driving distances.

--
Stephen T. Higgins, Ph.D.
Director, Vermont Center on Behavior and Health
Professor and Virginia H. Donaldson Chair in Translational Science
Departments of Psychiatry and Psychology
Vice Chair, Department of Psychiatry
University of Vermont
1 South Prospect Street
Burlington, VT 05401-1419




_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

[#DIV28SUPER] APA questions Food & Drug Administration=?utf-8?Q?=E2=80=99s_?=draft rules for tobacco research

ronaldwood@gmail.com* thought you'd like to see the following from the American Psychological Association. Page: APA questions Food & Drug Administration's draft rules for tobacco research http://www.apa.org/science/about/psa/2015/12/tobacco-research.aspx * The sender's email address has not been verified. www.apa.org | privacy statement | terms of use | contact APA

[#DIV28SUPER] Call for Nominations - Division 28 Awards

Hello again!

I am writing to encourage you to submit nomination materials for APA Division 28 Awards for the 2016 APA meeting in Denver.  Attached you will find the official call for nominations with the detailed instructions for each of the three awards:  Med Associates Brady-Schuster Award, Young Psychopharmacologist Award and Outstanding Dissertation Award.  These awards are an excellent way to recognize your outstanding colleagues in science- both the young and more seasoned!  The Awards Committee looks forward to seeing this year’s nominees.  The deadline for materials is January 15, 2016.  

 

Regards and Happy Holidays!

 

Cathy Stanger

 

Catherine Stanger, Ph.D.

Associate Professor

Department of Psychiatry

Geisel School of Medicine at Dartmouth

Rivermill Complex

85 Mechanic Street

Suite B3-1, HB7549

Lebanon, NH 03766

Catherine.stanger@dartmouth.edu

Phone 603-653-1819

Fax 603-448-5335

 

[#DIV28SUPER] Call for Articles for Special Issue

Dear Division 28 Members-

Please consider submitting a paper for the upcoming special issue of Experimental and Clinical Psychopharmacology.

Thanks,

Bill Stoops.

Call for Papers: Experimental and Clinical Psychopharmacology

 

Special Issue for August 2016 on:

50^th Anniversary of APA Division 28: The Past, Present and Future of Psychopharmacology and Substance Abuse

 

Division 28 was formed in 1966 to provide a home within APA for psychologists interested in the behavioral effects of psychoactive or central nervous system drugs and chemicals.  Today, the Division's overarching mission is to encourage the advancement of knowledge on the behavioral effects of psychotropic drugs and toxicants, including (a) disseminating research-based information on psychopharmacology and substance abuse within APA, in educational settings, and to other scientists; (b) encouraging the application of the results of psychopharmacology research to human affairs; and (c) consideration of education and policy issues pertaining to psychopharmacology, behavioral toxicology, and substance abuse. 

 

During 2016, we will celebrate the 50^th anniversary of Division 28. The proposed special issue will highlight the scientific contributions and historical milestones of APA's Division 28 and its members.  We invite manuscripts on the important scientific, clinical and translational contributions of Division 28 members, as well as commentary on the future of psychopharmacology and substance abuse research. In addition, collaborative, research-based manuscripts that disseminate new data about psychotropic drugs and toxicants are especially encouraged. Such papers could include novel research findings about the behavioral pharmacology of emerging drugs of abuse or newly developed compounds in non-human animals or humans (see [a], above). Research-based papers could also present new information on how aspects of psychopharmacology or substance abuse impact human affairs (see [b], above). Scholarly reflections on the notable changes that have occurred in the areas of psychopharmacology and substance abuse, particularly pertaining to education and policy (see [c], above), during the five decades since the Division was founded are also welcome.

 

Authors may submit primary research reports, review articles or commentaries to Experimental and Clinical Psychopharmacology to be considered for inclusion in this special issue. Manuscripts should be submitted as usual through the APA Online Submission Portal (www.apa.org/pubs/journals/pha/), and the cover letter should indicate that the authors wish the manuscript to be considered for publication in the special issue on the 50^th Anniversary of Division 28.  All submissions will undergo our normal peer review. Manuscripts received no later than March 1, 2016 will be considered for inclusion in the special issue. We strongly encourage individuals to contact us in advance with their ideas and ideally a draft title and abstract.

 

Questions or inquiries about the special issue can be directed to the Guest Editors of the issue, William W. Stoops, PhD, at william.stoops@uky.edu or Stacey C. Sigmon, PhD at stacey.sigmon@uvm.edu.  Correspondence can also be directed to the Editor, Suzette M. Evans, PhD at se18@cumc.columbia.edu.

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684

Associate Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.